Non-insulin dependent diabetic patients were studied to evaluate the effects of Beraprost sodium (sodium (±)-(1R, 2R, 3aS, 8bS)-2, 3, 3a 8b-tetrahydro-2-hydroxy-1-[(E)-(3S)-3-hydroxy-4-methyl-I-octen-6-ynyl]-1H-cyclopenta [b] benzofuran-5-butyrate) which is a stable analogue of PGI2, as a vasodilater and anti-platelet agent. Hemodynamic effects of this durg on the dorsal pedis artery were examined using a new real-time two-dimensional Doppoler echography techncque and laser blood flowmetry. Before, and 60 min and 90 min after, oral administration of Beraprost sodium (Dolne(R) 40μ, g) and Elastase (Elaszym (R) 1800 U), the cross-sectional area (A rea) of the dorsal pedis artery and its blood flow index (BFI), calculated from maximum flow velocity and area, were determined. Dermal microcirulatory blood vloume (MCBV) was also measured using the laser blood flowmeter. In the Beraprost sodium group, the area and the BFI were significantly increased. MCBV was also significantly increased. In the Elastase group, no significant changes were observed.(Talbe 2) From these results, it is suggested that Berarost sodium has beneficial effects on diabetic macro-and microangiopathy.